- One target, different effects: a comparison of distinct therapeutic antibodies against the same targets
-
Shim H
- KMID: 1123366
- Exp Mol Med.
- 2011 Oct;43(10):539-549.
- doi: 10.3858/emm.2011.43.10.063
To date, more than 30 antibodies have been approved worldwide for therapeutic use. While the monoclonal antibody market is rapidly growing, the clinical use of therapeutic antibodies is mostly limited... -
- CITED
-
- Close
- SHARE
-
- Close
- A chimeric antibody to L1 cell adhesion molecule shows therapeutic effect in an intrahepatic cholangiocarcinoma model
-
Lee ES, Jeong MS, Singh R, Jung J, Yoon H, Min JK, Kim KH, Hong HJ
- KMID: 1365906
- Exp Mol Med.
- 2012 Apr;44(4):293-302.
- doi: 10.3858/emm.2012.44.4.027
Intrahepatic cholangiocarcinoma (ICC), a malignant tumor derived from the intrahepatic bile duct epithelium, has a poor prognosis and is refractory to conventional chemotherapy and radiation therapy. Thus, there is an... -
- CITED
-
- Close
- SHARE
-
- Close
- Immune checkpoint blockade therapy for bladder cancer treatment
-
Kim J
- KMID: 2426521
- Investig Clin Urol.
- 2016 Jun;57(Suppl 1):S98-S105.
- doi: 10.4111/icu.2016.57.S1.S98
Bladder cancer remains the most immunogenic and expensive malignant tumor in the United States today. As the 4th leading cause of death from cancer in United States, Immunotherapy blocking immune... -
- CITED
-
- Close
- SHARE
-
- Close
